Recently stock market analysts have updated their consensus ratings on shares of Antares Pharma, Inc. (ATRS). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/09/2016 – Antares Pharma, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 3 price target on the stock.

09/25/2015 – Antares Pharma, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 4 price target on the stock.

05/18/2015 – Piper Jaffray began new coverage on Antares Pharma, Inc. giving the company a “overweight” rating. They now have a USD 3.5 price target on the stock.

05/14/2015 – Antares Pharma, Inc. was upgraded to “hold” by analysts at Zacks.

10/22/2014 – JMP Securities began new coverage on Antares Pharma, Inc. giving the company a “outperform” rating. They now have a USD 4 price target on the stock.

05/05/2014 – Antares Pharma, Inc. had its “buy” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 6 price target on the stock.

04/07/2014 – Antares Pharma, Inc. was downgraded to “sell” by analysts at TheStreet.

Antares Pharma, Inc. has a 50 day moving average of 0.90 and a 200 day moving average of 1.10. The stock’s market capitalization is 146.70M, it has a 52-week low of 0.67 and a 52-week high of 2.60.

The share price of the company (ATRS) was up +2.99% during the last trading session, with a high of 0.95 and the volume of Antares Pharma, Inc. shares traded was 440335.

View other investors thoughts on Antares Pharma, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.